knowledge -WSS

knowledge

author：comprehensive 2025-10-01 07:41:04 - browse：141

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： A Q&A with the global head of Boehringer Ingelheim's innovation unit

WSS

Kellogg’s is going to war over Mexico’s nutrition label rules

Vivek Ramaswamy made waves in the debate, much as in biotech

How the drug

Intellia plays down concerns on accidental germline transmission

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

As obesity drug market grows, telehealth companies court payers

leisure time

knowledge

focus

As demand for Covid shots wanes, Moderna seeks its next success

Senate panel eyes new effort on drug shortages

Jerome Adams on the need for new antivirals for Covid

Hospital at home shows how to bring innovation to health care

Activists slam private health insurers over coverage restrictions

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Virginia high school admissions case could be legal follow

Was Amgen transparent enough on FDA's concern on cancer drug?

New air purifier tech could be key to improving indoor air quality

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

explore

Intellia plays down concerns on accidental germline transmission

Was Amgen transparent enough on FDA's concern on cancer drug?

Trans patients at the end of life deserve respect and dignity

When women are denied an abortion, their children fare worse than peers

DeSantis wants to import drugs. Biden’s FDA blasted his plan

As obesity drug market grows, telehealth companies court payers

Wikipedia

explore

Wikipedia

explore